Cover Image
市場調查報告書

大容量皮下藥物輸送

High Volume Subcutaneous Drug Delivery

出版商 Greystone Research Associates 商品編碼 358327
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
大容量皮下藥物輸送 High Volume Subcutaneous Drug Delivery
出版日期: 2016年05月24日 內容資訊: 英文
簡介

本報告提供開發給長時間的皮下注射用的具大容量投藥要求的治療用注射劑之相關詳細分析,治療需求的促進要素分析,設備簡介,開發中的大容量皮下藥物的調查,市場資料、預測,注射藥、設備的主要企業簡介,及經濟、技術、規定要素的評估等彙整資料。

摘要整理

市場機會

  • 藥物輸送市場動態
  • 人口統計的變化
  • 邁向自我施打的趨勢
  • 門診病人的注射成本、庫存負擔
  • 設備設計的創新
  • 治療需求的促進要素
  • 競爭情形
  • 風險因素

大容量皮下市場區分

  • 大容量投藥
  • 持續時間依賴型投藥

設備的設計因素

  • 人因工程/人體工學
  • 可用性
  • 安全性
  • 警報/用戶的回饋
  • 拋棄式 vs. 可重複使用
  • 電子產品 vs. 機器
  • 第一藥物容器
  • 冷凍乾燥藥

主要的治療領域

  • 抗生素
    • scPharmaceuticals
    • Autoimmune
    • AstraZeneca
  • 心臟
    • scPharmaceuticals
    • Insulet
    • Hematology
    • Amgen
    • UCB
  • 免疫
    • CSL Behring
    • Octapharma
    • Grifols
    • Bio Products Laboratory
  • 代謝疾病
    • Metabolic Conditions
    • GlaxoSmithKline
    • Rhythm Metabolic
    • Italfarmaco
  • 神經學
    • AbbVie
    • NeuroDerm
    • Britannia
    • US Worldmeds
  • 癌症
    • Janssen
    • Roche
  • 其他治療市場區隔
    • UCB Pharma
    • 武田藥品工業

企業簡介

目錄
Product Code: HVS383K

The trend favoring biological drugs as a percent of all drugs continues to accelerate. Most are injectables and many require volumes that exceed 1 mL per dose, the de facto limit for comfortable and safe patient self-administration. As result, the majority of biologicals are supplied for delivery via infusion. The demographics of patient populations and the current trend in therapeutic drug development are converging to create an increasingly steep demand curve for infusion. The costs and logistics of this convergence are a major driver of the efforts to develop and commercialize high volume drug delivery products that can be administered subcutaneously. We expect the number of therapeutic drugs in this class to grow significantly by the end of the decade, creating significant opportunities for high volume subcutaneous drug delivery products.

What You Will Learn

  • Provides detailed analysis of therapeutic injectables with high volume dosing requirements that have been developed for subcutaneous administration over extended time periods.
  • Analyzes therapeutic demand drivers and evaluates product activity in eleven product segments
  • Profiles devices for delivering high volume drugs subcutaneously and assesses design factors and material selection issues
  • Examines high volume subcutaneous drug products in development, and analyzes their potential commercial impact
  • Provides market data and forecasts to 2020
  • Profiles injectable drug and device participants, their product development activities, business strategies, and corporate alliances and affiliations
  • Evaluates the impact of economic, technology, and regulatory factors

Table of Contents

Executive Summary

The Market Opportunity

  • Drug Delivery Market Dynamics
  • Shifting Demographics
  • The Trend toward Self-Administration
  • The Cost and Logistical Burden of Out-patient Infusion
  • Innovation in Device Designs
  • Therapeutic Demand Drivers
  • Competitive Landscape
  • Risk Factors

High Volume Subcutaneous Market Segments

  • High Volume Dosing
  • Duration Dependent Dosing

Device Design Factors

  • Human Engineering/Ergonomics
  • Usability
  • Safety
  • Alerts/User Feedback
  • Disposable vs. Reusable
  • Electronic vs. Mechanical
  • Primary Drug Container
  • Lyophilized Drugs/Reconstitution

Key Therapeutic Sectors

  • Antibiotics
  • scPharmaceuticals
  • Autoimmune
  • AstraZeneca
  • Cardiology
  • scPharmaceuticals
  • Insulet
  • Hematology
  • Amgen
  • UCB
  • Immunology
  • CSL Behring
  • Octapharma
  • Grifols
  • Bio Products Laboratory
  • Metabolic Conditions
  • GlaxoSmithKline
  • Rhythm Metabolic
  • Italfarmaco
  • Neurology
  • AbbVie
  • NeuroDerm
  • Britannia
  • US Worldmeds
  • Oncology
  • Janssen
  • Roche
  • Other Therapeutic Segment
  • UCB Pharma
  • Takeda

Company Profiles

Back to Top